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This study examined androgen receptor (AR) gene amplification and protein expression in 102 matched paired hormone sensitive
and resistant tumours from 51 patients. AR gene amplification and X chromosome copy number were assessed by fluorescent in situ
hybridisation, and protein expression was assessed by immunohistochemistry. All tumours were stained for PSA protein expression.
Significantly more tumours exhibited AR amplification following the development of hormone resistance (20%, 10 out of 49)
compared to matched hormone-sensitive tumours from the same patient (2%, one out of 48) (P¼0.0085). The level of AR
expression was significantly higher in hormone-resistant tumours compared to matched hormone-sensitive tumours from the same
patient (130, interquartile range, 55–167 vs 94.5 interquartile range, 55–120, P¼0.019). AR expression levels in hormone-resistant
tumours with and without AR amplification were not significantly different. However, an increase in AR expression was seen with the
development of AR amplification in paired tumours. The rate of AR gene amplification and/or an increase in AR protein expression
during androgen resistant is too low to wholly explain the development of androgen resistance. Alternative mechanisms for
modulating the function of the AR, or other signalling pathways, must be considered as key factors in the development of hormone-
resistant prostate.
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Prostate cancer is the second most frequent cause of male cancer-
related deaths (Goktas et al, 1999). Androgens regulate prostate
gland growth and differentiation by binding to the androgen
receptor (AR), which regulates a network of androgen responsive
genes for example, PSA. Prostate cancer growth is also stimulated
by androgens (Gregory et al, 1998), and can be inhibited by AR
antagonists (antiandrogens) or surgical castration (Avila et al,
2001). Approximately 70–80% of prostate cancer patients treated
with antiandrogens respond favourably in the first instance
(Goktas et al, 1999). This effect is however, transient (Newling
et al, 1997) with the majority of patients developing androgen
resistance (Newling et al, 1997). The mechanisms involved with the
development of resistance are poorly understood, but AR
mutations (Avila et al, 2001), AR amplification (Visakorpi et al,
1995), increased AR expression (Gregory et al, 1998) and
activation of the AR by interaction with other signalling pathways
have been implicated (Culig et al, 1998).
Androgen receptors are present in all epithelial cells of the
prostate. Downregulation of AR expression during prostate cancer
progression (Segawa et al, 2001) and increased expression with the
development of hormone refractory tumours (Trapman and
Cleutjens, 1997; Latil et al, 2001; Linja et al, 2001) have both been
reported. AR expression has been reported to predict which
patients will respond to hormone therapy and to correlate with
tumour grade, stage and progression-free survival (Trapman and
Cleutjens, 1997; Koivisto and Helin, 1999; Linja et al, 2001) . It has
been postulated that AR protein expression is increased due to AR
amplification by a gene dosage effect resulting in the development
of androgen resistance. AR gene copy number has been demon-
strated to correlate positively with PSA expression (Koivisto and
Helin 1999). Polysomy of chromosome X ranges from 42 to 60%
and amplification of the AR gene ranges from 20 to 30% in
hormone-resistant prostate tumours (Koivisto et al, 1997; Buben-
dorf et al, 1999; Miyoshi et al, 2000; Edwards et al, 2001). However,
there is still no clear investigation into AR gene amplification and
AR protein expression in hormone-sensitive and hormone-
resistant prostate cancer, using paired tumours from the same
patient.
MATERIALS AND METHODS
Patients
A total of 51 patients (102 matched tumours) were retrospectively
selected for analysis; all tumours had patient identification
removed including block number and hospital number and were
coded in order to make the database anonymous. In 20 cases, AR
fluoresence in situ hybridisation results only have been previously
reported (Edwards et al, 2001). Ethical approval was obtained from Received 13 January 2003; revised 24 April 2003; accepted 7 May 2003
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ythe multicentre research ethics committee (MREC) for Scotland
and the appropriate local research and ethical committees (LREC)
for use of matched hormone-sensitive and hormone-resistant
tumours in our study. All patients received conventional androgen
deprivation therapy (orchidectomy, antiandrogens or androgen
ablation therapy). Patients were selected for analysis if they
initially responded to treatment (response was defined by prostate-
specific antigen (PSA) levels falling by at least 50%), but
subsequently relapsed. Patients were classed as having hormone
escaped cancer when sustained rising PSA levels were noted and
were selected for study if a post-hormone relapse sample was
available. The initial tumour sample was either a transurethral
resection of the prostate (TURP) or a transrectal ultrasound-
guided biopsy (TRUS); however, the relapsed tumour sample was
always a TURP which was performed to treat clinical symptoms.
PSA values and full clinical follow-up was available for each
patient, tumours were assigned Gleason Scores by a single
pathologist (KMG).
Fluorescence in situ hybridisation
Sections (5mm) cut from archival formalin-fixed, paraffin-
embedded tissue were placed on aminopropyltriethoxysilane
(silane)-treated slides. The slides were pretreated on a VP2000
robotic slide processor (Vysis, UK, Ltd), as previously described
14
using dual labelling (X chromosome, Spectrum Greent labelled
CEP X, Vysis, UK, Ltd and AR, Spectrum Oranget labeled probe
locus Xq11-13, Vysis, UK, Ltd).
The normal range for X chromosome and AR copy number were
identified using the mean chromosomal copy number from 14
benign prostatic hyperplasia (BPH). Amplification was defined as
an AR:X ratio greater than 1.5 (Edwards et al, 2001).
Immunohistochemistry (IHC)
Prostate-specific antigen and AR protein expression was deter-
mined in paraffin-embedded tissue sections by IHC with a
standard immunoperoxidase procedure. Antigen retrial was
performed by microwaving under pressure for 5min in TE buffer.
A purified immunoglobulin fraction of either a rabbit antiserum to
human PSA (A 0562, DAKO, Denmark 2mgml
 1) or AR (NCL-AR-
2F12, Vector, UK, 1mgml
 1) was used as the primary antibodies.
In each case, an isotype-matched antibody was used as a negative
control in which no staining was observed. Positive control
sections were included in each IHC assay. Bound antibody was
visualised by the streptavidin–biotin (ABC kit, Vector Labs, UK)
method including diaminobenzidine as a chromogen (DAKO).
Staining was scored blind by two independent observers using a
weighted histoscore method (Fraser et al, 2003), interclass
correlation coefficients (ICCC) were calculated and confirmed
acceptable correlation between observer scores (Armitage and
Berry, 1995). ICCC values for histoscores were 0.67 (good) and 0.91
(excellent) for PSA and AR staining, respectively (Armitage and
Berry, 1995). Staining was defined as increased or decreased only
in those samples with a difference between paired samples of
greater than 2  the mean observer variation for the parameter
under investigation.
Statistics
The Fisher’s exact test was used to compare FISH results pre- and
post-hormone resistance. Prostate-specific antigen protein expres-
sion and AR protein expression are shown as median and
interquartile ranges. Paired Student’s t-tests were used to compare
PSA and AR expression between pre- and post-hormone-resistant
tumours. Wilcoxon signed-rank test was used to compare Gleason
sum between paired hormone-sensitive and hormone-resistant
tumours. Comparisons between the resistant tumours with and
without AR gene amplification were made with the Mann–
Whitney test and w
2 test for linear trends. Correlations between AR
gene copy number and PSA MHS (mean histoscore) and AR MHS
or PSA MHS and AR MHS and Gleason sum were calculated using
the Spearman rank test.
RESULTS
Patient information
Of the 51 patients analysed, seven had bone metastases at the time
of initial hormone therapy: 102 tumours were analysed. Gleason
sum in hormone-sensitive tumours was significantly lower than in
hormone-resistant tumours (Po0.001) (Table 1), although some
commentators question the value of Gleason scores in hormone-
relapsed disease. Mean patient age at diagnosis was 69 (41–83)
years, and median follow-up was 1669 days (interquartile range,
1062–2428). Median time to hormone relapse was 899 (inter-
quartile range, 537–1689).
FISH results
Figure 1 illustrates an example of a prostate cancer tumour with
AR gene amplification. A total of 97 tumours were analysed by
Table 1 Gleason sum of hormone-sensitive and hormone-resistant prostate tumours
Hormone-sensitive prostate cancer Hormone-resistant prostate cancer P-value
Gleason sum p6 24% (12/51) 4% (5/51)
Gleason sum¼7 27% (14/51) 12% (7/51)
Gleason sum X8 49% (25/51) 78% (40/51) o0.001
P-values were obtained comparing Gleason sums between paired hormone-sensitive and hormone-resistant tumours by
Wilcoxon signed-ranks test. NB: Some observers question the value of Gleason sums in hormone-relapsed disease.
Figure 1 A prostate cancer tumour with AR gene amplification is shown.
AR amplification in prostate cancer nuclei (stained with DAPI, blue)
showing increased copies of both AR (red) and chromosome X (green).
Magnification  1000.
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five cases were not analysed as we were unable to successfully FISH
them as they were fixed in Bouins). Significantly more hormone-
resistant tumours had AR amplification (20%, 10 out of 49) than
hormone-sensitive tumours (2%, one out of 48) (P¼0.0085)
(Table 2). In the amplified tumours, the median AR:X chromo-
some ratio was 3.11 (interquartile range, 2.4–5.8). In 22 patients,
no abnormalities of either the X chromosome or AR copy number
were detected in either the biopsy taken before or after hormone
relapse. In all, 18 (38%) hormone-sensitive tumours and 23 (47%)
hormone-relapsed tumours (P¼0.46) had increased copies of the
X chromosome (Table 2). A total of 15 (31%) hormone-sensitive
tumours and 25 (51%) hormone-relapsed tumours (P¼0.075)
showed evidence of increased AR gene copies (Table 2). There was
no significant difference between the level of gene or chromosome
copy numbers with the development of hormone refractory
disease. Gleason sum was not significantly different in hormone-
resistant tumours with and without AR amplifications (Table 3).
There was no significant difference in time to relapse in patients
with AR amplifications (median 1143, interquartile range, 230–
1731) compared to those without AR amplifications (median 857,
interquartile range 541–1709).
IHC results
Figure 2 illustrates an example of AR protein expression in
hormone-resistant prostate tumours. The median AR histoscore
was 108 (interquartile range, 55–153), the level of AR expression
was significantly higher in hormone-resistant tumours compared
to matched hormone-sensitive tumours (median 130, interquartile
range, 55–167 vs median 94.5 interquartile range, 55–120,
P¼0.019) (Table 2) with overlap between groups. There was no
significant difference in time to relapse in patients where AR
expression increased (median 907, interquartile range 485–1653)
compared to those where AR expression was unchanged or
decreased (median 836, interquartile range, 496–1914).
Four samples did not express AR protein. In one of the
hormone-resistant cases, the previous hormone-sensitive biopsy
showed both AR amplification (2.9) and a mean AR histoscore of
140. Following the development of androgen resistance, the AR
amplification ratio did not change (3.09); however, no AR
expression was detected in either of the two post-treatment
biopsies from this patient. PSA expression remained unchanged in
the transition from hormone-sensitive to hormone-resistant
disease (Table 2).
AR expression levels in hormone-resistant tumours with and
without AR amplification are not significantly different (Table 4).
However, an increase in AR expression was seen in 80% (eight out
of 10) of the cases (Figure 3A) with AR amplification compared to
only 35% of cases without AR amplification (Figure 3B). Using
Spearman’s rank correlation, AR expression in hormone-sensitive
and hormone-resistant prostate cancer did not correlate with
either Gleason sum or PSA expression.
All tumours included in this study expressed PSA. The median
PSA histoscore was 146 (range¼108–167), the level of PSA
expression was significantly lower in hormone-resistant tumours
compared to matched hormone-sensitive tumours (P¼0.018;
Table 2).
Table 2 AR gene amplification rate, AR protein expression and PSA expression in hormone-sensitive and
hormone-resistant prostate cancer
Hormone-sensitive prostate cancer Hormone-resistant prostate cancer P-value
AR copy no. 31% (15/48) 51% (25/49) 0.075
X copy no. 33% (18/48) 47% (23/49) 0.46
Amplified 2% (1/48) 20% (10/49) 0.0085
AR MHS 94.5 (55–120) 130 (55–167) 0.019
PSA MHS 158 (121–185) 132 (101–168) 0.018
AR/X copy no.¼percentage of cases with increased AR or chromosome X copy number when compared with BPH.
Amplified¼percentage of cases with AR:X ratios above 1.5. MHS¼median histoscore for androgen receptor or PSA IHC
(interquartile ranges in brackets).
Table 3 Gleason sums in hormone-resistant prostate cancer tumours with and without AR amplification
AR normal (38 cases) AR amplified (10 cases) P-value
Gleason sum p6 23% (9/38) 0% (0/10)
Gleason sum¼7 32% (12/38) 10% (1/10)
Gleason sum X8 45% (17/38) 90% (9/10) 0.423
AR amplification¼AR:X ratio greater than 1.5, AR normal¼AR:X ratio within normal range. The Mann–Whitney test
was used to establish if there was a significant difference in Gleason sum in tumours with or without AR amplification.
Figure 2 A prostate cancer tumour that expresses AR protein is shown.
AR protein expression is coloured brown and is present in the tumour cell
nuclei. Magnification  400.
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Androgen receptor gene amplifications are uncommon in hor-
mone-sensitive tumours and are present in 20–30% of hormone-
resistant tumours (Visakorpi et al, 1995; Koivisto et al, 1997;
Bubendorf et al, 1999; Miyoshi et al, 2000; Edwards et al, 2001). In
the present study, we investigated AR amplification, AR protein
expression and PSA expression in paired hormone-sensitive and
hormone-resistant tumours from the same patient with documen-
ted initial responses to androgen deprivation therapy. We confirm
here that a significant increase in AR gene amplification rates is
seen in the transition from hormone-sensitive to hormone-
resistant disease (P¼0.0085); however, this is only observed in a
proportion of cases. Based on our results and those from previous
studies between 70 and 80% of cases with hormone relapse must
therefore involve mechanisms other than amplification of the AR.
While patients with AR gene amplification may represent a readily
identifiable, and possibly treatable, group more research should be
focused on alternative mechanisms of hormone escape. This is
especially relevant as we have also identified a patient with AR
amplification in the hormone-sensitive tumour, which responds
fully to therapy, suggesting that AR amplification does not
preclude a response to androgen deprivation therapy. In the light
of this observation it is possible, though at present unproven and
to our view unlikely, that AR amplification does not mediate
hormone resistance.
It is hypothesised that AR gene amplification is involved in the
development of hormone-resistant prostate cancer due to ampli-
fication, resulting in an increase in AR protein expression
(Visakorpi et al, 1995). Real-time RT–PCR demonstrated that
even one additional copy of the AR gene may increase AR
expression (Linja et al, 2001), suggesting that even a small increase
in relative gene dosage could have biological significance.
However, in the study by Linja no correlation between AR mRNA
and protein levels was performed. Similarly in a separate study,
Latil et al, (2001) also describe increased AR mRNA levels in
hormone escaped tumours. Both studies are important in that they
demonstrate increases in AR mRNA in prostate cancers. However,
neither study documents protein expression or makes use of
paired samples from individual patients. An increase in AR protein
expression is postulated to enable low circulating levels of
androgens that are present following orchidectomy or treatment
with LHRH agonists, to activate the AR even in the presence of
antiandrogens (Koivisto et al, 1997). We therefore measured AR
protein expression as well as AR amplification status in our patient
cohort. As we have a unique data set of matched hormone-
sensitive and hormone-resistant tumours from each patient and
therefore enabling us to follow AR protein expression with the
development of resistance in the same patient and relate this to AR
amplification status, stringent quality controls (see above) were
included to validate IHC results. Our study confirms that AR
expression increases as the disease progresses to its hormone
refractory state (P¼0.019) and that 80% of cases in which AR
amplification was observed also exhibited an increase in AR
expression. However, an increase in AR expression was also seen
in 35% of cases that did not develop AR amplification. This
suggests that although an increase in AR expression is associated
with AR amplification, an increase in expression may also be due
Table 4 Comparison of AR and PSA expression levels in hormone-resistant prostate cancer with and
without AR amplification
AR normal (38 cases) AR amplified (10 cases) P-value
Median age (years) 70 (67–75) 66 (63–70) 0.29
Time to relapse 857 (541–1709) 1641 (306–1746) 0.6
AR IHC 121 (53–156) 172 (129–191) 0.9
PSA IHC 135 (109–160) 97 (85–162) 0.3
AR amplified¼AR:X ratio greater than 1.5, AR normal¼AR:X ratio within normal range; median age¼median age at
diagnosis of AR amplified or normal cases (interquartile range in brackets); time to relapse¼median time to relapse (in
days) of AR amplified or normal cases (interquartile range in brackets); AR/PSA IHC¼median AR or PSA histoscores for
both groups (interquartile ranges in brackets).
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Figure 3(A) The AR protein mean histoscore for matched hormone-
sensitive and hormone-resistant tumours with AR amplification is shown.
The cases shown with unbroken lines are those cases that developed AR
amplification in the transition from hormone-sensitive to hormone-resistant
disease. All cases had an increase in AR protein expression with the
development of AR amplification, However, only eight out of the nine cases
significantly increased. The case shown with the broken line had AR gene
amplification in the hormone-sensitive and hormone-resistant tumour. This
case had a significant decrease in AR protein expression with the
development of hormone resistance. (B) The AR protein mean histoscore
for 41 matched hormone-sensitive and hormone-resistant tumours with
out AR amplification are shown. In 14 out of 41 (35%) cases, AR
expression increased markedly with the development of hormone relapse.
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degradation or an increase in protein stabilisation. Almost half
of all patients do not show any increase in AR expression during
the development of hormone-resistant disease. We also identified a
patient with AR amplification in both hormone-sensitive and
hormone-resistant tumours and three cases with loss of AR protein
expression at the development of hormone resistance, as observed
by Gnanapragasam et al, (2002). Therefore, increased androgen
receptor expression, by whatever mechanism, can at best only
explain hormone resistance in a subgroup of prostate cancer cases.
Alternative mechanisms of hormone resistance are activation of
AR via phosphorylation (Zhu and Liu 1997; Lin et al, 2001),
therefore increasing AR activity without effecting its expression
levels or may bypass the AR, for example, AP-1 phosphorylation
(Henttu and Vihko, 1998; Krishna et al, 2002).
While PSA expression was significantly lower in hormone-
sensitive tumours compared to hormone-resistant tumours
(P¼0.018), this decrease was marginal with considerable overlap
between values for pre- and post-hormone-resistant tumours
(Table 1). The significance of this finding is therefore unclear and
requires further investigation.
This is the first study to our knowledge that has correlated AR
gene amplification, AR protein expression and PSA protein
expression in matched hormone-sensitive and hormone-resistant
prostate cancer. We have confirmed that AR gene amplification is
associated with the development of hormone resistance in 20% of
patients and this is related to an increase in AR expression in the
majority of cases. We have also demonstrated that this is not the
only mechanism by which AR expression is increased and also that
in almost 60% of cases, AR expression remains unchanged or
decreases. Therefore, in these cases, hormone resistance must be
due to alternative mechanisms of AR activation or may be due to
mechanisms that can stimulate AR responsive genes independent
of the AR.
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